Kornimate/medical-research-clean huggingface dataset:
acute cardiovascular events triggered by covid-19-related stress

Conditions: Acute Myocardial Infarction; Ventricular Tachycardia; Sudden Cardiac Death; Stroke, Acute

Summary: the current covid19 pandemic has afflicted almost the whole globe. the stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. this study is a cross sectional study that will enroll patients evaluated during the covid19 pandemic period for acute cardiovascular events.

the onset of acute myocardial infarction (ami) is a complex interplay of internal circadian factors and external physical and emotional triggers. these interactions may lead to rupture of an often non-occlusive vulnerable atherosclerotic coronary plaque with subsequent formation of an occlusive thrombus. physical and emotional stresses are important triggers of acute cardiovascular events including ami. triggering events, internal changes, and external factors vary among different geographical, environmental, and ethnic regions. life-style changes, pharmacotherapy, and psychological interventions may potentially modify the response to, and protect against the effects of triggering events. certain times in the life span of different communities all around the world are prone to natural and man-made disasters that, not only have direct negative impact on human lives and state-resources, but also have indirect impact on triggering acute cardiovascular events during the time of the disaster and the period immediately after. for example, earthquakes, wars, and terrorist attacks, in addition to direct human life loss and destruction of communities, have bees associated with a surge in the number of acute mi, sudden cardiac death, ventricular tachy-arrhythmia and implantable cardiovertor defibrillators (icd) discharges. the current covid-19 pandemic has afflicted almost the whole globe. the virus can directly attack the myocyte and cause various degrees of cardiac damage and cardiovascular clinical entities. however, the stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psycho-social stresses such as extreme physical effort, lock down, anger, fear, financial stress, sorrow, death of a significant person..etc. this study is a cross sectional study that will enroll patients evaluated during the covid-19 pandemic period for acute cardiovascular events not directory related to the virus infectivity, who voice certain and specific trigger(s) related to the pandemic impact on social life and physical activity.

Eligibility criteria:
inclusion criteria: * age \>18 years. * acute mi (stemi and nstemi). * sudden cardiac death * ventricular tachycardia * icd shocks. * stressful trigger prior to the cardiovascular event exclusion criteria: \* covid-19 infection.

Keywords: covid-19 triggered myocardial infarction triggered acute cardiovascular events covid-19-related stress
npo before sedation

Conditions: Pediatric ALL

Summary: pre-procedural fasting is routinely conducted to prevent pulmonary aspiration regarding sedation or anesthesia. however, prolonged fasting cause hypoglycemia, dehydration, nausea, and patient discomfort. moreover, because children have small reserved energy, prolonged fasting need to be prohibited. therefore, this study is designed to investigate the safety and efficacy of new fasting policy allowing water until 1 hour before sedation compared to the standard fasting time (4 hours of fasting including water).


Eligibility criteria:
inclusion criteria: * children scheduled for elective echocardiography * aged under 3 years old exclusion criteria: * comorbidity other than hear disease or chromosomal disease * patients with delayed gastric emptying * patients with structural abnormalities of the stomach or esophagus * difficult airway management * parents refuse to participate in the study * unable to achieve sedation * neonatal
concomitant use and staggered use of vaccine and oral poliovirus (opv) in healthy infants (v260-014)(completed)

Conditions: Rotavirus Infections; Gastroenteritis

Summary: the study is being conducted to demonstrate that vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with oral polio vaccine (opv) without impairing the safety or immunogenicity of either vaccine.


Eligibility criteria:
inclusion criteria: * infants in good health exclusion criteria: * previous administration of any oral poliovirus vaccine (opv) and rotavirus vaccine * receipt of inactivated poliovirus vaccine (ipv) prior to the first dose of either study vaccine, or at any time during the course of the study * any condition resulting in depressed immunity * any allergy to any vaccine component as stated in the package circulars * allergies to polymyxin b, neomycin or any other antibiotics * receipt of intramuscular, oral, or intravenous corticosteroid treatment * history of congenital abdominal disorders, intussusception, or abdominal surgery; clinical evidence of active gastrointestinal illness * history of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive * prior receipt of a blood transfusion or blood products, including immunoglobulin * fever, with a rectal temperature of ≥38.1°c (≥ 100.5°f) at the time of immunization * infants residing in a household with an immunocompromised person
safety and performance of the cardiovalve tr replacement system

Conditions: Tricuspid Regurgitation

Summary: the objective of this study is to evaluate the safety and performance of cardiovalve tr system

the study is a multi-center, prospective, single arm study designed to evaluate the safety and performance of the cardiovalve tricuspid valve replacement system

Eligibility criteria:
inclusion criteria: * functional tr ≥3+ * symptomatic, nyha class ii-iva * patient approved by the subject screening committee exclusion criteria: * cardiac anatomy deemed not suitable for the cardiovalve tr system * hemodynamic instability * severe right ventricular failure * refractory heart failure requiring advanced intervention

Keywords: tricuspid valve heart valve cardiovascular disease
a study of the addition of avastin (bevacizumab) to carboplatin and paclitaxel therapy in patients with ovarian cancer

Conditions: Ovarian Cancer

Summary: this open-label, non-comparative, multi-center study will assess the safety profile and efficacy of avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in participants with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma. participants will receive 15 milligrams/kilogram (mg/kg) avastin intravenously (iv) on day 1 of every cycle for up to 36 cycles of 3 weeks each, carboplatin (area under the plasma concentration-time curve \[auc\] 5-6 mg/ml/min) on day 1 every 3 weeks for a maximum of 8 cycles and paclitaxel 175 milligram per square meter (mg/m\^2) on day 1 every 3 weeks or 80 mg/m\^2 every week for a maximum of 8 cycles. the anticipated time on study drug will be 108 weeks or until disease progression or unacceptable toxicity.


Eligibility criteria:
inclusion criteria: * histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma or clear cell carcinoma or carcinosarcoma. participants with recurrent ovarian cancer who have been previously treated with surgery alone for their early stage disease are eligible. * eastern cooperative oncology group performance status (ecog ps) of 0, 1 or 2 * life expectancy greater than or equal to (\>=3) months exclusion criteria: * participants with non-epithelial ovarian cancer, ovarian tumors with low malignant potential (i.e., borderline tumors), or synchronous primary endometrial carcinoma * previous systemic therapy for ovarian cancer. prior neo-adjuvant chemotherapy is allowed * planned intraperitoneal cytotoxic chemotherapy * radiotherapy within 28 days of day 1, cycle 1 * major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to first dose of avastin * history or evidence of national cancer institute common terminology criteria for adverse events (nci ctcae) grade \>=1 arterial thromboembolic event or grade \>=3 venous thromboembolic event within 6 months prior to enrollment
the effects of fluoxetine and/or dhea

Conditions: Type 1 Diabetes Mellitus

Summary: (1) to determine how the selective serotonin reuptake inhibitor (ssri), fluoxetine (prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) to learn how a hormone, dehydroepiandrosterone (dhea), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). dhea is a hormone produced naturally in the human body. however, it can be manufactured and is sold as an over-the-counter dietary supplement. the dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) to study combined effects of fluoxetine and dhea during low blood glucose. in the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or dhea or fluoxetine and dhea or a placebo (a pill with no fluoxetine or dhea). approximately 64 individuals with type 1 diabetes will take part in this study.


Eligibility criteria:
inclusion criteria: * 64 (32 males, 32 females) t1dm patients aged 18-50 yr. * hba1c \< 11.0% * no clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc) * body mass index \< 40kg · m-2 exclusion criteria: * pregnancy * subjects unable to give voluntary informed consent * subjects on anticoagulant drugs, anemic or with known bleeding diatheses * subjects taking any of the following medications will be excluded: non-selective beta blockers, sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants, mood stabilizers, cns stimulants, opioids, hallucinogens * subjects with a recent medical illness or past history of severe depression, mania or psychotic disease * subjects that score greater than 50 on the depression scale * subjects unwillingness or inability to comply with approved contraception measures * abnormal results following screening tests and physical examination that are clinically significant * subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents * clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, s-t segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old. * pneumonia * hepatic failure/jaundice * creatinine greater than 1.6 mg/dl * acute cerebrovascular/ neurological deficit * fever greater than 38 °c screening laboratory tests exclusion criteria * hematocrit lower than 32 * wbc lower than 3 thou/ul or greater than 14 thou/ul * liver function tests: sgot and sgpt greater than twice upper limit of normal range (i.e. greater than 80 u/l). * tbil greater than 2 mg/dl * alkaline phosphatase greater than 150u/l * positive hiv, hep b, hep c * hepatic transaminase \> 2x normal
single dose of 1% tropicamide and 10% phenylephrine for pupillary dilation

Conditions: Eye Diseases

Summary: the purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination.

to the best of the authors' knowledge, there have been no clinical trials using an appropriate regimen for pupillary dilation up until now. therefore, the authors were interested to find out the most appropriate regimen for complete ocular examination, based on the finding that a pupil diameter of 6 mm or greater is adequate for indirect ophthalmoscopy. the authors hypothesize that a single dose of 1% tropicamide and 10% phenylephrine is adequate to complete the job and are conducting this prospective randomized clinical controlled trial to prove the hypothesis.

Eligibility criteria:
inclusion criteria: * aged between 20 and 80 years old * dark iris * require binocular indirect ophthalmoscopy for complete ocular examination * signed written consent forms exclusion criteria: * history of ocular trauma * history of intraocular surgery * history of laser treatment * previous eye drop instillation that may affect pupillary dilation * ocular diseases that may affect pupil size such as horner's syndrome, adies' pupil, glaucoma and uveitis * history of diabetes mellitus, severe hypertension and cardiovascular diseases

Keywords: single dose mydriatic drug pupillary dilation
efficacy analysis of tigecycline-based therapy and polymyxin b-based therapy in icu infection

Conditions: Tigecycline; Polymyxin B; Intensive Care Unit

Summary: the gender, age, icu diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in icu, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin b admitted to the icu of four provincial-level grade a hospitals in changsha, hunan province ,china from 2017 to 2021 were included. to analyze the therapeutic effect of tigecycline-based or polymyxin b-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.

the gender, age, icu diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in icu, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin b admitted to the icu of four provincial-level grade a hospitals in changsha, hunan province ,china from 2017 to 2021 were included. the four hospitals included the 1st-3th xiangya hospitals and hunan provincial people's hospital. organize the data.patients with a course of treatment \ 0.05.

Eligibility criteria:
inclusion criteria: * icu patients receiving tigecycline or polymyxin b treatment; * age 14-95, gender unlimited; * there are clear infections and strains; * the patient and/or his/her family agree to sign the informed consent voluntarily. exclusion criteria: * patients with treatment of less than 4 days; * patients with abscission; * pregnant patients; * patients with age \ 95 years.
vascular function in the framingham third generation

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to investigate the role of endothelial dysfunction and increased vascular stiffness as contributors to the pathogenesis of cardiovascular disease.

background: increasingly, researchers understand that endothelial dysfunction and increased vascular stiffness contribute to the pathogenesis of cardiovascular disease (cvd). the framingham heart study (fhs) has been examining vascular function in about 3600 middle-aged and elderly participants of the fhs offspring and minority omni cohorts. design narrative: the study characterizes vascular function by performing noninvasive studies of endothelial function with brachial ultrasound flow-mediated dilation, and of vascular stiffness with arterial tonometry, in 3850 adult offspring of the fhs offspring and omni cohorts. the total of over 7000 vascular examinations in an extensively studied multi-generational community-based cohort provides the opportunity to characterize the environmental and genetic determinants, and the prognosis of altered vascular function. the study hypotheses are: vascular function is determined by both environmental and genetic factors; endothelial function and vascular stiffness phenotypes are associated with each other: and vascular dysfunction predisposes to the development of hypertension (htn) and cardiovascular disease.

Eligibility criteria:
no eligibility criteria
prevalence of pe in ed patients with isolated syncope

Conditions: Syncope

Summary: syncope is a rapid onset, transient, loss of consciousness with a short duration. this symptom has been reported to be a specific presentation of patients with pulmonary embolism. however, the prevalence of pulmonary embolism in patients with syncope remains debated. this prospective cohort study will recruit patients presenting to the emergency department with a syncope, who will systematically undergo formal workup for pulmonary embolism. the main objective of this study is to assess the prevalence of pulmonary embolism in ed patients with syncope

syncope is a rapid onset, transient, loss of consciousness with a short duration. this symptom has been reported to be a specific presentation of patients with pulmonary embolism. however, the prevalence of pulmonary embolism in patients with syncope remains debated. this prospective cohort study will recruit patients presenting to the emergency department with a syncope, who will systematically undergo formal workup for pulmonary embolism. the main objective of this study is to assess the prevalence of pulmonary embolism in ed patients with syncope

Eligibility criteria:
inclusion criteria: * age \>= 18 years visiting the emergency department, * history of syncope in the past 24 hours: loss of consciousness, rapid onset, short duration (\<1 min), transient, with spontaneous and rapid recovery without post event confusion * with or without prodromes * without any other obvious cause * informed written consent * affiliation to a social security system (ame excepted) exclusion criteria: - other criteria for pe suspicion : acute onset of dyspnea acute severe chest pain, * pregnancy * concurrent anticoagulation treatment * other obvious cause of syncope : seizure, stroke, traumatic brain injury , toxic intake , atrioventricular block type 3

Keywords: syncope pulmonary embolism emergency department clinical decision rule
sam - skip a meal - insulin glargine, diabetes mellitus type 1

Conditions: Diabetes Mellitus, Type 1

Summary: primary objective: to compare metabolic control as measured by blood glucose (bg) upon arising from bed (7:00 am - 12:00 pm) in type 1 diabetes mellitus patients who skip the morning meal during treatment with mdi basal/bolus insulin: difference of change of blood glucose between 7:00 am and 11:00 am between patients on insulin glargine and nph insulin. secondary objective: to perform an evaluation between the two patient groups for bg (10:00 pm and 12:00 pm) as well as for serum insulin, free fatty acid levels and β-hydroxybutyrate (7:00 am - 12:00 pm).


Eligibility criteria:
inclusion criteria: patients with type 1 diabetes mellitus who have been treated with mdi (multiple daily injection) basal/bolus insulin, regular insulin/short acting insulin analogue + nph insulin on a stable dose (no change more than 10 %) for at least 4 weeks prior to study entry, who have an hba1c smaller/equal 9 % (measured at visit 1) and a bmi smaller/equal 35 kg/m2. in addition, patients must have a fbg value at day 1 before skipping meal (6:00 am - 07:00 am) between 90 - 120 mg/dl (5.0 - 6.5 mmol/l). exclusion criteria: * breast-feeding * history of hypersensitivity to the study medication or to drugs with similar chemical structures * likelihood of requiring treatment during the study period with drugs not permitted by the study protocol * treatment with any investigational drug in the last 30 days before study entry * clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult * history of drug or alcohol abuse no subjects who have previously been treated with insulin glargine will be enrolled in this study.
measurement of respiratory admittance for pediatric asthma diagnosis

Conditions: Asthma

Summary: the purpose is to characterize the change of respiratory admittance induced by salbutamol inhalation in children and young adults. a variation threshold will be fixed to distinguish asthmatic and healthy subjects. this project could allow a better identification of asthmatic individuals needing a treatment, a reduction of morbidity of asthma, a reduction of unnecessary treatments administered in individuals with respiratory but not asthmatic symptoms, a better comprehension of bronchial hyperreactivity and its role in asthmatic disease.


Eligibility criteria:
inclusion criteria: asthmatic children group: * several episodes of paroxysmal wheezes, spontaneous or after exercise, without bronchial-pulmonary infection * absence of bronchodilator taking during last 12 hours * absence of reported intolerance to adrenergic substances * parental authorization and consent of child to participate to the study control children group: - parental authorization and consent of child to participate to the study control adult group: - consent to participate to the study exclusion criteria: control children and adult groups: * at least 2 episodes of wheezes during breathing * several wheezes, abnormal breathlessness, cough during physical exercise * asthma diagnosed by family doctor * administration of drugs to treat asthma * eczema or food allergy at inclusion * episode of cough for longer than 6 weeks, without bronchial infection * bronchitis, throat infection, rhino-pharyngitis during last 15 days * paleness or cyanosis with loss of consciousness when the child was a baby or during an exercise
study of efficacy and safety of hb0017 in patients with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled, phase iii clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of hb0017 injection in the treatment of moderate to severe plaque psoriasis in adults.


Eligibility criteria:
inclusion criteria: * male or female subjects aged 18-75 years (inclusive) * chronic plaque psoriasis (pso) for at least 6 months prior to the randomization. * psoriasis area severity index (pasi) \>=12 and body surface area (bsa) affected by pso \>=10% and static physician global assessment (spga) score \>=3. * subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator * subjects who are able to use effective contraception from the screening period to 6 months after the last dose key exclusion criteria: * forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline * drug-induced psoriasis * ongoing use of prohibited treatments * any active infection (other than common cold) within 14 days * serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization * have previously received any drug that directly targets il-17 or il-17 receptor * have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-il-12/anti-il-23 or anti-il-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization * a history of inflammatory bowel disease or other serious autoimmune disease * previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency

Keywords: psoriasis; hb0017